A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection

Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, a recombinant chimeric protein ChimT was developed based on T-cell epitopes identified from the immunogenic L...

Descripción completa

Detalles Bibliográficos
Autores principales: Lage, Daniela P., Vale, Danniele L., Linhares, Flávia P., Freitas, Camila S., Machado, Amanda S., Cardoso, Jamille M. O., de Oliveira, Daysiane, Galvani, Nathália C., de Oliveira, Marcelo P., Oliveira-da-Silva, João A., Ramos, Fernanda F., Tavares, Grasiele S. V., Ludolf, Fernanda, Bandeira, Raquel S., Pereira, Isabela A. G., Chávez-Fumagalli, Miguel A., Roatt, Bruno M., Machado-de-Ávila, Ricardo A., Christodoulides, Myron, Coelho, Eduardo A. F., Martins, Vívian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317424/
https://www.ncbi.nlm.nih.gov/pubmed/35891310
http://dx.doi.org/10.3390/vaccines10071146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317424/
https://www.ncbi.nlm.nih.gov/pubmed/35891310
http://dx.doi.org/10.3390/vaccines10071146

Ejemplares similares